https://scholars.lib.ntu.edu.tw/handle/123456789/496664
標題: | Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling | 作者: | Zhong W.-B. Liang Y.-C. CHIH-YUAN WANG TIEN-CHUN CHANG Lee W.-S. |
公開日期: | 2005 | 卷: | 12 | 期: | 3 | 起(迄)頁: | 615-629 | 來源出版物: | Endocrine-Related Cancer | 摘要: | Lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase, inhibits the conversion of mevalonate from HMG-CoA. Previously, we have reported that lovastatin treatment induced the occurrence of apoptosis and differentiation in ARO anaplastic thyroid cancer cells. Here, we demonstrated that lovastatin inhibited the ARO cell invasiveness and delineated the underlying molecular mechanism. Lovastatin significantly suppressed the EGF-induced cell adhesion, actin filament reorganization and transmigration. Lovastatin also reduced EGF-induced increases in the levels of phosphorylated p125FAK and paxillin. These inhibitory effects mediated by lovastatin can be prevented by pretreatment of the cells with mevalonate or geranylgeraniol (GGOH), but not farnesol (FOH). Accordingly, the consuming and depletion of geranylgeranyl pyrophosphate and consequent suppression of the protein geranylgeranylation, which is essential for activation of Rho GTPases, might account for the lovastatin-induced inhibition of cell motility and invasion. Western blot analysis showed that lovastatin inhibited membrane translocation of Rho (e.g. RhoA and Rac1) through decreasing post-translational geranylgeranyl modification of Rho. In addition, treatment of the cells with specific inhibitors against Rho (Clostridium botulinum C3 transferase) or ROCK (Y-27632) abolished the GGOH-mediated prevention of, and restored the lovastatin-induced decrease of cell invasion. Taken together, our results suggested that lovastatin suppressed EGF-induced ARO cell invasiveness through the reduction of Rho geranylgeranylation, which in turn suppressed the membrane translocation, and subsequent suppression of Rho/ROCK and FAK/paxillin signaling. ? 2005 Society for Endocrinology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-26944457329&doi=10.1677%2ferc.1.01012&partnerID=40&md5=9f34ab4bc452b0011c67d57892d347f0 https://scholars.lib.ntu.edu.tw/handle/123456789/496664 |
ISSN: | 1351-0088 | DOI: | 10.1677/erc.1.01012 | SDG/關鍵字: | 3 hydroxy 3 methylglutaryl coenzyme A; 4 (1 aminoethyl) n (4 pyridyl)cyclohexanecarboxamide; epidermal growth factor; farnesol; focal adhesion kinase; geranylgeraniol; geranylgeranyl pyrophosphate; hydroxymethylglutaryl coenzyme A reductase inhibitor; mevalonic acid; mevinolin; paxillin; protein kinase inhibitor; protein p125 FAK; Rac1 protein; Rho factor; Rho guanine nucleotide binding protein; Rho kinase; RhoA guanine nucleotide binding protein; transferase; unclassified drug; actin filament; apoptosis; article; cancer invasion; cell adhesion; cell differentiation; cell line; cell migration; cell motility; cell strain ARO; controlled study; drug mechanism; enzyme activation; human; human cell; protein geranylgeranylation; protein localization; protein modification; protein phosphorylation; protein processing; signal transduction; thyroid cancer; Western blotting; Actins; Antineoplastic Agents; Collagen; Drug Combinations; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Laminin; Lovastatin; Neoplasm Invasiveness; Proteoglycans; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Thyroid Neoplasms; Tumor Cells, Cultured |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。